{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:37:40Z","timestamp":1726497460687},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Neurology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.pediatrneurol.2011.11.020","type":"journal-article","created":{"date-parts":[[2012,1,28]],"date-time":"2012-01-28T03:10:36Z","timestamp":1327720236000},"page":"83-88","source":"Crossref","is-referenced-by-count":16,"title":["Vigabatrin for Childhood Partial-Onset Epilepsies"],"prefix":"10.1016","volume":"46","author":[{"given":"Hansel M.","family":"Greiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Fordyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Agricola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Tudor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Neal","family":"Franz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib1","series-title":"Sabril [package insert]","year":"2010"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","article-title":"A\u00a0double-blind, placebo-controlled study of vigabatrin three g\/day in patients with uncontrolled complex partial seizures: Vigabatrin Protocol 024 Investigative Cohort","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib3","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1528-1157.1999.tb01991.x","article-title":"Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures","volume":"40","author":"Dean","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib5","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: Final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib6","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: A multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: A retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/088307389901400201","article-title":"Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: Literature review","volume":"14","author":"Hancock","year":"1999","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib10","first-page":"CD007302","article-title":"Vigabatrin for refractory partial epilepsy","volume":"16","author":"Hemming","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1034\/j.1600-0420.2003.00023.x","article-title":"Vigabatrin-associated visual field constriction in a longitudinal series: Reversibility suggested after drug withdrawal","volume":"81","author":"Fledelius","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1528-1167.2006.00422.x","article-title":"Vigabatrin retinopathy in an Irish cohort: Lack of correlation with dose","volume":"47","author":"Kinirons","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejpn.2007.03.010","article-title":"Current role of vigabatrin in infantile spasms","volume":"11","author":"Parisi","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"Br Med J [Clin Res]"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib15","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib16","first-page":"469","article-title":"Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: A prospective study","volume":"249","author":"Schmitz","year":"2002","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib17","first-page":"1658","article-title":"Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients with epilepsy","volume":"46","author":"Gonzalez","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/NDT.S5236","article-title":"Treatment of refractory complex partial seizures: Role of vigabatrin","volume":"5","author":"Waterhouse","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/11317650-000000000-00000","article-title":"Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: Final results from an open-label, observational, multicentre study","volume":"23","author":"Wild","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib21","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00148581-200810050-00004","article-title":"Current management of tuberous sclerosis complex","volume":"10","author":"Krueger","year":"2008","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/archneur.57.5.662","article-title":"National Institutes of Health consensus conference: Tuberous sclerosis complex","volume":"57","author":"Hyman","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/088307389901400610","article-title":"Tuberous Sclerosis Consensus Conference: Recommendations for diagnostic evaluation","volume":"14","author":"Roach","year":"1999","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.410170307","article-title":"Gamma-vinyl GABA: A double-blind placebo-controlled trial in partial epilepsy","volume":"17","author":"Gram","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1528-1157.1986.tb03512.x","article-title":"Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy","volume":"27","author":"Loiseau","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(84)92112-3","article-title":"Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy","volume":"1","author":"Rimmer","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1528-1157.1986.tb03600.x","article-title":"Vigabatrin in the treatment of epilepsy: A double-blind, placebo-controlled study","volume":"27","author":"Tartara","year":"1986","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.pediatrneurol.2011.11.020_bib29","first-page":"S52","article-title":"Therapeutic trial of vigabatrin in refractory infantile spasms","volume":"6","author":"Chiron","year":"1991","journal-title":"J\u00a0Child Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-2008-1071585","article-title":"Vigabatrin in newly diagnosed infantile spasms","volume":"25","author":"Schmitt","year":"1994","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: A randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2010.09.004","article-title":"Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy","volume":"92","author":"Sergott","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/112067211002000419","article-title":"Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy","volume":"20","author":"Ak\u00e7akaya","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ana.21526","article-title":"Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity","volume":"65","author":"Jammoul","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib36","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: A U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"issue":"Suppl. 192","key":"10.1016\/j.pediatrneurol.2011.11.020_bib37","first-page":"136","article-title":"Vigabatrin therapy for infantile spasms: Review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/01658100903582498","article-title":"Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin","volume":"34","author":"Sergott","year":"2010","journal-title":"Neuroophthalmology"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archneur.63.1.122","article-title":"Epilepsy in patients with Angelman syndrome caused by deletion of the chromosome 15q11\u201313","volume":"63","author":"Valente","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pediatrneurol.2011.11.020_bib40","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/08830738040190070701","article-title":"Severe myoclonic epilepsy in infancy: Toward an optimal treatment","volume":"19","author":"Ceulemans","year":"2004","journal-title":"J\u00a0Child Neurol"}],"container-title":["Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887899411005078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887899411005078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T20:27:10Z","timestamp":1561235230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887899411005078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0887899411005078"],"URL":"https:\/\/doi.org\/10.1016\/j.pediatrneurol.2011.11.020","relation":{},"ISSN":["0887-8994"],"issn-type":[{"value":"0887-8994","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}